146 related articles for article (PubMed ID: 37102765)
21. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
Choi HSJ; Sonneveld MJ; Farag MS; Brouwer WP; Brakenhoff SM; Hirode G; Gehring AJ; de Man RA; Hansen BE; Janssen HLA
J Viral Hepat; 2021 Dec; 28(12):1729-1737. PubMed ID: 34514678
[TBL] [Abstract][Full Text] [Related]
22. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
Chen GY; Zhu MF; Zheng DL; Bao YT; Wang J; Zhou X; Lou GQ
World J Gastroenterol; 2014 Jul; 20(25):8195-200. PubMed ID: 25009392
[TBL] [Abstract][Full Text] [Related]
23. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
24. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
Tatsukawa Y; Tsuge M; Kawakami Y; Hiyama Y; Murakami E; Kurihara M; Nomura M; Tsushima K; Uchida T; Nakahara T; Miki D; Kawaoka T; Abe-Chayama H; Imamura M; Aikata H; Ochi H; Hayes CN; Kawakami H; Chayama K
Antivir Ther; 2018; 23(8):639-646. PubMed ID: 29856363
[TBL] [Abstract][Full Text] [Related]
25. Bushen Formula promotes the decrease of HBsAg levels in patients with CHB by regulating Tfh cells and B-cell subsets.
Ji L; Wei J; Zhang R; Zhang X; Gao Y; Fang M; Yu Z; Cao L; Gao Y; Li M
J Ethnopharmacol; 2024 Jun; 328():118072. PubMed ID: 38508431
[TBL] [Abstract][Full Text] [Related]
26. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
27. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
Liem KS; van Campenhout MJH; Xie Q; Brouwer WP; Chi H; Qi X; Chen L; Tabak F; Hansen BE; Janssen HLA
Aliment Pharmacol Ther; 2019 Feb; 49(4):448-456. PubMed ID: 30689258
[TBL] [Abstract][Full Text] [Related]
28. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
29. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
[TBL] [Abstract][Full Text] [Related]
31. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients.
Xun Z; Liu C; Yu QQ; Lin JP; Huang JL; Yang TW; Wu WN; Wu SH; Ou QS
Clin Chim Acta; 2020 Mar; 502():120-127. PubMed ID: 31891671
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
[TBL] [Abstract][Full Text] [Related]
33. Long Term HBsAg Responses to Peg-Interferon Alpha-2b in HBeAg Negative Chronic Hepatitis B Patients Developing Clinical Relapse after Stopping Long-Term Nucleos(t)ide Analogue Therapy.
Kumar K; Jindal A; Gupta E; Trehanpati N; Shasthry SM; Maiwall R; Arora V; Bhardwaj A; Kumar G; Kumar M; Sarin SK
J Clin Exp Hepatol; 2024; 14(1):101272. PubMed ID: 38076362
[TBL] [Abstract][Full Text] [Related]
34. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
35. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients.
Wang WX; Jia R; Gao YY; Liu JY; Luan JQ; Qiao F; Liu LM; Zhang XN; Wang FS; Fu J
Front Immunol; 2022; 13():894410. PubMed ID: 35958609
[TBL] [Abstract][Full Text] [Related]
36. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
37. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
38. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
39. Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients.
Li M; Zhang L; Xie S; Sun F; Zeng Z; Deng W; Jiang T; Bi X; Lin Y; Yang L; Lu Y; Shen G; Liu R; Wu S; Chang M; Hu L; Dong J; Yi W; Xie Y
Front Immunol; 2022; 13():892031. PubMed ID: 35603222
[TBL] [Abstract][Full Text] [Related]
40. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.
Li H; Wang H; Peng C; Zheng X; Liu J; Weng ZH; Yang DL
J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):547-555. PubMed ID: 28786051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]